{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:24Z","timestamp":1791005784648,"version":"4.1.0"},"reference-count":99,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Angioimmunoblastic T cell lymphoma (AITL) is a common subtype of mature peripheral T cell lymphoma (PTCL). As per the 2016 World Health Organization classification, AITL is now considered as a subtype of nodal T cell lymphoma with follicular helper T cells. The diagnosis is challenging and requires a constellation of clinical, laboratory and histopathological findings. Significant progress in the molecular pathophysiology of AITL has been achieved in the past two decades. Characteristic genomic features have been recognized that could provide a potential platform for better diagnosis and future prognostic models. Frontline therapy for AITL was mainly depending on chemotherapy and the management of relapsed or refractory AITL is still unsatisfactory with a very poor prognosis. Upfront transplantation offers better survival. Novel agents have been introduced recently with promising outcomes. Several clinical trials of combinations using novel agents are underway. Herein, we briefly review recent advances in AITL diagnosis and the evolving treatment landscape.<\/jats:p>","DOI":"10.3390\/curroncol28060456","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:23:47Z","timestamp":1640060627000},"page":"5480-5498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma"],"prefix":"10.3390","volume":"28","author":[{"given":"Mostafa F.","family":"Mohammed Saleh","sequence":"first","affiliation":[{"name":"Adult Hematology, Transplantation and Cellular Therapy Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"},{"name":"Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kotb","sequence":"additional","affiliation":[{"name":"Adult Hematology, Transplantation and Cellular Therapy Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"},{"name":"Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada E. M.","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2532","authenticated-orcid":false,"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[{"name":"Adult Hematology, Transplantation and Cellular Therapy Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Adult Hematology, Transplantation and Cellular Therapy Section, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000040811","article-title":"Angioimmunoblastic lymphadenopathy with dysproteinemia: Emphasis on pathogenesis and treatment","volume":"99","author":"Sallah","year":"1998","journal-title":"Acta Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.4081\/hr.2017.7088","article-title":"Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection","volume":"9","author":"Facchinelli","year":"2017","journal-title":"Hematol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","article-title":"Angioimmunoblastic T-cell lymphoma: Histological progression associates with EBV and HHV6B viral load","volume":"138","author":"Zhou","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4132\/jptm.2017.03.15","article-title":"Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification","volume":"51","author":"Kim","year":"2017","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4274\/tjh.galenos.2018.2018.0023","article-title":"EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma","volume":"36","author":"Bostankolu","year":"2019","journal-title":"Turk. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5021\/ad.2016.28.6.789","article-title":"A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma","volume":"28","author":"Lee","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17763","DOI":"10.18632\/oncotarget.14846","article-title":"Angioimmunoblastic T cell lymphoma: Novel molecular insights by mutation profiling","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xu, B., and Liu, P. (2014). No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: A population-based study of 1207 cases. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092585"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: Analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190601123989","article-title":"Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma","volume":"48","author":"Park","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I Diagnose Angioimmunoblastic T-Cell Lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","article-title":"Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: Clinical correlation and insights into natural history and disease progression","volume":"31","author":"Attygalle","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): A new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2559.1993.tb00491.x","article-title":"Usefulness of follicular dendritic cell pattern in classification of peripheral T-cell lymphomas","volume":"23","author":"Leung","year":"1993","journal-title":"Histopathology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","article-title":"CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified","volume":"40","author":"Onaindia","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","article-title":"Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma","volume":"141","author":"Nelson","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cas.13393","article-title":"Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma","volume":"109","author":"Fukumoto","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-017-0047-2","article-title":"Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways","volume":"8","author":"Willemsen","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12185-015-1738-8","article-title":"Multistep tumorigenesis in peripheral T cell lymphoma","volume":"102","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","article-title":"Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms","volume":"4","author":"Lewis","year":"2020","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"ref_29","first-page":"2642","article-title":"Detection of immunoglobulin and T-cell receptor gene rearrangements in angioimmunoblastic T-cell lymphoma","volume":"11","author":"Zhu","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: Final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/10428194.2020.1845336","article-title":"Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: A retrospective study from the national hospital organization in Japan","volume":"62","author":"Yamasaki","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: A multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cam4.2742","article-title":"EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma","volume":"9","author":"Eladl","year":"2020","journal-title":"Cancer Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Joly","year":"2012","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3960\/jslrt.17019","article-title":"Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma","volume":"57","author":"Fujisawa","year":"2017","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref_39","first-page":"4502489","article-title":"The Incremental Prognostic Value of Baseline 18F-FDG PET\/CT Imaging in Angioimmunoblastic T-Cell Lymphoma","volume":"2020","author":"Wang","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, G., Zhao, X., Hu, Y., Tan Su Yin, E., Chen, D., Wang, H., and Zhao, K. (2021). The role of pre-treatment and mid-treatment 18F-FDG PET\/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). BMC Med. Imaging, 21.","DOI":"10.1186\/s12880-021-00674-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/10428194.2016.1236380","article-title":"Value of interim FDG PET\/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma","volume":"58","author":"Moon","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs. CHOPE for treatment of peripheral T-cell lymphoma: A meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","article-title":"Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma","volume":"1","author":"Kim","year":"2017","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: A comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41389-020-00259-x","article-title":"New preclinical models for angioimmunoblastic T-cell lymphoma: Filling the GAP","volume":"9","author":"Mhaidly","year":"2020","journal-title":"Oncogenesis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.18.00511","article-title":"Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma","volume":"15","author":"Moskowitz","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: A phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab\u2013CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Lugtenburg","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","article-title":"CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: Final analysis of a prospective phase II trial","volume":"92","author":"Binder","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: The DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2020","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1\/2 Phase III Trials","volume":"132","author":"Altmann","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2015.11.008","article-title":"Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study","volume":"16","author":"Buckstein","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2018-99-110354","article-title":"Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2147\/OTT.S297539","article-title":"Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report","volume":"14","author":"Hu","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_61","first-page":"892","article-title":"Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: Results in 12 patients","volume":"5","author":"Siegert","year":"1991","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: An Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-134440","article-title":"Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","article-title":"The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: A prospective, multicenter, single arm, phase 1b\/2 study","volume":"18","author":"Zhang","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1758835920923829","DOI":"10.1177\/1758835920923829","article-title":"Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients","volume":"12","author":"Sun","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: A retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed\/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent to Treat","volume":"106","author":"Horwitz","year":"2005","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.14740\/jh459w","article-title":"Efficacy of ESHAP Regimen in Transplant Ineligible Patients with Relapsed\/Refractory T-Cell Lymphoma","volume":"7","author":"Norasetthada","year":"2018","journal-title":"J. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Milpied","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/blood.V126.23.4392.4392","article-title":"Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience","volume":"126","author":"Chou","year":"2015","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: Long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: A CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1097\/HS9.0000000000000187","article-title":"Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS","volume":"3","author":"Gregory","year":"2019","journal-title":"Hemasphere"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/08998280.2019.1668720","article-title":"Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion","volume":"33","author":"Sawhney","year":"2020","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ejh.12053","article-title":"Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide","volume":"90","author":"Beckers","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","article-title":"Cyclosporine for angioimmunoblastic T-cell lymphoma: A literature review","volume":"12","author":"Ohmoto","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Reboursiere, E., and Damaj, G. (2018). Bendamustine in peripheral T-cell lymphoma. Ann. Lymphoma, 2.","DOI":"10.21037\/aol.2018.04.01"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAS.0b013e3181cc7e79","article-title":"PD-1 expression in T-cell lymphomas and reactive lymphoid entities: Potential overlap in staining patterns between lymphoma and viral lymphadenitis","volume":"34","author":"Krishnan","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: An open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cyto.b.21881","article-title":"Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms","volume":"100","author":"Berg","year":"2021","journal-title":"Cytom. Part B Clin. Cytom."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:08Z","timestamp":1760169008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":99,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060456"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060456","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}